Anoopjit Singh Kooner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anoopjit Singh Kooner has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Hai Yu
Department of Chemistry, University of California-Davis, Davis, CA, USA
8 shared publications - Xi Chen
Department of Chemistry, University of California-Davis, Davis, CA, USA
8 shared publications - James W. Janetka
Department of Biochemistry and Molecular Biophysics Washington University School of Medicine St. Louis MO 63110 USA
3 shared publications - Michael P. Mannino
Department of Biochemistry and Molecular Biophysics Washington University School of Medicine St. Louis MO 63110 USA
3 shared publications - Xiaohong Yang
Department of Chemistry University of California, Davis One Shields Avenue Davis 95616 USA
3 shared publications - Yue Yuan
Department of Chemistry University of California One Shields Avenue Davis, California 95616 United States
3 shared publications
Latest Publications
- 3 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14365-14389
Lead Optimization of TgCDPK1 Inhibitors for the Treatment of Toxoplasmosis
Toxoplasma gondii is an important opportunistic pathogen that infects many individuals and threatens the health of those with compromised immunity. Current therapies are unable to eradicate chronic infections and pose risks of adverse reactions. Using X-ray structure-based drug design, we have developed a new series of biaryl-substituted pyrazolopyrimidine inhibitors of the essential parasite enzyme calcium-dependent protein kinase 1 (TgCDPK1). These inhibitors have excellent potency against the enzyme and in vitro antiparasitic activity. We further optimized the compounds for increased metabolic stability, lowered plasma protein binding, decreased efflux, and improved pharmacokinetics (PK). Several of the inhibitors had desirable PK with high oral bioavailability, low clearance, and extended half-life, leading to excellent compound exposure in the plasma and brain over a 24-h period. Three compounds were tested during acute infection in both immunocompetent and immunocompromised mice. We identified 16c as a promising preclinical candidate to treat toxoplasmosis.
- 3 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14365-14389
Lead Optimization of TgCDPK1 Inhibitors for the Treatment of Toxoplasmosis
Toxoplasma gondii is an important opportunistic pathogen that infects many individuals and threatens the health of those with compromised immunity. Current therapies are unable to eradicate chronic infections and pose risks of adverse reactions. Using X-ray structure-based drug design, we have developed a new series of biaryl-substituted pyrazolopyrimidine inhibitors of the essential parasite enzyme calcium-dependent protein kinase 1 (TgCDPK1). These inhibitors have excellent potency against the enzyme and in vitro antiparasitic activity. We further optimized the compounds for increased metabolic stability, lowered plasma protein binding, decreased efflux, and improved pharmacokinetics (PK). Several of the inhibitors had desirable PK with high oral bioavailability, low clearance, and extended half-life, leading to excellent compound exposure in the plasma and brain over a 24-h period. Three compounds were tested during acute infection in both immunocompetent and immunocompromised mice. We identified 16c as a promising preclinical candidate to treat toxoplasmosis.
- 4 November 2025
- Published by Wiley in Angewandte Chemie
- Vol. 138 (1)
Acinetobacter baumannii α2–6‐Legionaminyltransferase‐Catalyzed Synthesis Reveals Legionaminic Acid Form Selectivity by Antibodies in Pooled Human IgGs
Legionaminic acids (Legs) are prokaryote‐specific nine‐carbon acidic monosaccharides belonging to the nonulosonic acid (NulO) family. Various Leg forms are found in the polysaccharides or glycoproteins produced by numerous pathogenic bacteria, including capsular polysaccharides of carbapenem‐resistant Acinetobacter baumannii . Hypothetic legionaminyltransferases have been predicted from gene sequences but none has been biochemically validated. In this study we report the first biochemical characterization of a legionaminyltransferase. We demonstrate that AbGtr18 from an A. baumannii K8 strain is a donor promiscuous α2–6‐legionaminyltransferase selective for α‐ N ‐acetylgalactosamine‐glycoside (GalNAcαOR) acceptors. In addition, streamlined chemical synthetic routes, including regio‐selective triflylation and azide substitution processes, were developed to prepare precursors or chemoenzymatic synthons of various forms of Legs. Applying the novel α2–6‐legionaminyltransferase AbGtr18 in one‐pot multienzyme (OPME) synthesis with or without additional chemical derivatization enabled rapid construction of a focused library of NulO‐glycosides (NulOα2–6GalNAcαOR) containing nine NulO forms. Binding and inhibition studies with these compounds revealed selective Leg forms recognized by the antibodies in the pooled human immunoglobulin (IgGs), reflecting natural occurrence of these Leg forms and indicating their prior encounters by human immune systems. AbGtr18 thus emerges as both a potential target for antibiotic development and a powerful biocatalyst for accessing synthetically challenging NulO‐glycosides with therapeutical potentials.
- 4 November 2025
- Published by Wiley in Angewandte Chemie
- Vol. 138 (1)
Acinetobacter baumannii α2–6‐Legionaminyltransferase‐Catalyzed Synthesis Reveals Legionaminic Acid Form Selectivity by Antibodies in Pooled Human IgGs
Legionaminic acids (Legs) are prokaryote‐specific nine‐carbon acidic monosaccharides belonging to the nonulosonic acid (NulO) family. Various Leg forms are found in the polysaccharides or glycoproteins produced by numerous pathogenic bacteria, including capsular polysaccharides of carbapenem‐resistant Acinetobacter baumannii . Hypothetic legionaminyltransferases have been predicted from gene sequences but none has been biochemically validated. In this study we report the first biochemical characterization of a legionaminyltransferase. We demonstrate that AbGtr18 from an A. baumannii K8 strain is a donor promiscuous α2–6‐legionaminyltransferase selective for α‐ N ‐acetylgalactosamine‐glycoside (GalNAcαOR) acceptors. In addition, streamlined chemical synthetic routes, including regio‐selective triflylation and azide substitution processes, were developed to prepare precursors or chemoenzymatic synthons of various forms of Legs. Applying the novel α2–6‐legionaminyltransferase AbGtr18 in one‐pot multienzyme (OPME) synthesis with or without additional chemical derivatization enabled rapid construction of a focused library of NulO‐glycosides (NulOα2–6GalNAcαOR) containing nine NulO forms. Binding and inhibition studies with these compounds revealed selective Leg forms recognized by the antibodies in the pooled human immunoglobulin (IgGs), reflecting natural occurrence of these Leg forms and indicating their prior encounters by human immune systems. AbGtr18 thus emerges as both a potential target for antibiotic development and a powerful biocatalyst for accessing synthetically challenging NulO‐glycosides with therapeutical potentials.
- 4 November 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (1) , e19750
Acinetobacter baumannii α2–6‐Legionaminyltransferase‐Catalyzed Synthesis Reveals Legionaminic Acid Form Selectivity by Antibodies in Pooled Human IgGs
Legionaminic acids (Legs) are prokaryote‐specific nine‐carbon acidic monosaccharides belonging to the nonulosonic acid (NulO) family. Various Leg forms are found in the polysaccharides or glycoproteins produced by numerous pathogenic bacteria, including capsular polysaccharides of carbapenem‐resistant Acinetobacter baumannii . Hypothetic legionaminyltransferases have been predicted from gene sequences but none has been biochemically validated. In this study we report the first biochemical characterization of a legionaminyltransferase. We demonstrate that AbGtr18 from an A. baumannii K8 strain is a donor promiscuous α2–6‐legionaminyltransferase selective for α‐ N ‐acetylgalactosamine‐glycoside (GalNAcαOR) acceptors. In addition, streamlined chemical synthetic routes, including regio‐selective triflylation and azide substitution processes, were developed to prepare precursors or chemoenzymatic synthons of various forms of Legs. Applying the novel α2–6‐legionaminyltransferase AbGtr18 in one‐pot multienzyme (OPME) synthesis with or without additional chemical derivatization enabled rapid construction of a focused library of NulO‐glycosides (NulOα2–6GalNAcαOR) containing nine NulO forms. Binding and inhibition studies with these compounds revealed selective Leg forms recognized by the antibodies in the pooled human immunoglobulin (IgGs), reflecting natural occurrence of these Leg forms and indicating their prior encounters by human immune systems. AbGtr18 thus emerges as both a potential target for antibiotic development and a powerful biocatalyst for accessing synthetically challenging NulO‐glycosides with therapeutical potentials.
- 4 November 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (1) , e19750
Acinetobacter baumannii α2–6‐Legionaminyltransferase‐Catalyzed Synthesis Reveals Legionaminic Acid Form Selectivity by Antibodies in Pooled Human IgGs
Legionaminic acids (Legs) are prokaryote‐specific nine‐carbon acidic monosaccharides belonging to the nonulosonic acid (NulO) family. Various Leg forms are found in the polysaccharides or glycoproteins produced by numerous pathogenic bacteria, including capsular polysaccharides of carbapenem‐resistant Acinetobacter baumannii . Hypothetic legionaminyltransferases have been predicted from gene sequences but none has been biochemically validated. In this study we report the first biochemical characterization of a legionaminyltransferase. We demonstrate that AbGtr18 from an A. baumannii K8 strain is a donor promiscuous α2–6‐legionaminyltransferase selective for α‐ N ‐acetylgalactosamine‐glycoside (GalNAcαOR) acceptors. In addition, streamlined chemical synthetic routes, including regio‐selective triflylation and azide substitution processes, were developed to prepare precursors or chemoenzymatic synthons of various forms of Legs. Applying the novel α2–6‐legionaminyltransferase AbGtr18 in one‐pot multienzyme (OPME) synthesis with or without additional chemical derivatization enabled rapid construction of a focused library of NulO‐glycosides (NulOα2–6GalNAcαOR) containing nine NulO forms. Binding and inhibition studies with these compounds revealed selective Leg forms recognized by the antibodies in the pooled human immunoglobulin (IgGs), reflecting natural occurrence of these Leg forms and indicating their prior encounters by human immune systems. AbGtr18 thus emerges as both a potential target for antibiotic development and a powerful biocatalyst for accessing synthetically challenging NulO‐glycosides with therapeutical potentials.
- 25 September 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (18)
Front Cover: Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors (ChemMedChem 18/2025)
- 25 September 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (18)
Front Cover: Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors (ChemMedChem 18/2025)
- 8 August 2025
- Published by Wiley in ChemMedChem
- p. e202500440
Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors
Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii and poses grave health concern for immunocompromised patients. T. gondii has a family of calcium dependent protein kinases (CDPKs) that control a variety of critical processes. Among these, TgCDPK1 is required for parasite motility, cell invasion, and egress and hence is essential both for in vitro growth of T. gondii and to cause infections in animals. Using existing X‐ray cocrystal structures of pyrazolopyrimidine (PP) inhibitors bound to TgCDPK1, six new chemical series of inhibitors are rationally designed. The synthesis of analogs based on the most promising novel series is pursued, which resulted in potent TgCDPK1 inhibitors that effectively block parasite growth in cells. The resulting lead compounds 44 and 45 belonging to the imidazopyrazine chemical series demonstrate the promising potential of this new class of inhibitors for the treatment and possible cure of the Toxoplasmosis.
- 8 August 2025
- Published by Wiley in ChemMedChem
- p. e202500440
Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors
Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii and poses grave health concern for immunocompromised patients. T. gondii has a family of calcium dependent protein kinases (CDPKs) that control a variety of critical processes. Among these, TgCDPK1 is required for parasite motility, cell invasion, and egress and hence is essential both for in vitro growth of T. gondii and to cause infections in animals. Using existing X‐ray cocrystal structures of pyrazolopyrimidine (PP) inhibitors bound to TgCDPK1, six new chemical series of inhibitors are rationally designed. The synthesis of analogs based on the most promising novel series is pursued, which resulted in potent TgCDPK1 inhibitors that effectively block parasite growth in cells. The resulting lead compounds 44 and 45 belonging to the imidazopyrazine chemical series demonstrate the promising potential of this new class of inhibitors for the treatment and possible cure of the Toxoplasmosis.
- Open Access
The sialome of the retina, alteration in age-related macular degeneration (AMD) pathology and potential impacts on Complement Factor H
Purpose: Little is known about sialic acids of the human retina, despite their integral role in self/non-self-discrimination by complement factor H (CFH), the alternative complement pathway inhibitor. Methods: A custom sialoglycan microarray was used to characterize the sialic acid-binding specificity of native CFH or recombinant molecules where IgG Fc was fused to CFH domains 16-20 (contains a sialic acid-binding site), domains 6-7 (contains a glycosaminoglycan-binding site) or the CFH-related proteins (CFHRs) 1 and 3. We analyzed macular and peripheral retinal tissue from post-mortem ocular globes for amount, type, and presentation (glycosidic linkage type) of sialic acid in individuals with age-related macular degeneration (AMD) and age-matched controls using fluorescent lectins and antibodies to detect sialic acid and endogenous CFH. Released sialic acids from neural retina, retinal pigmented epithelium (RPE) cells and the Bruch’s membrane (BrM) were labelled with 1,2-diamino-4,5-methylenedioxybenzene-2HCl (DMB), separated and quantified by high-performance liquid chromatography (DMB-HPLC). Results: Both native CFH and the recombinant CFH domains 16-20 recognized Neu5Ac and Neu5Gc that is α2-3-linked to the underlying galactose. 4- O -Actylation of sialic acid and sulfation of GlcNAc did not inhibit binding. Different linkage types of sialic acid were localized at different layers of the retina. The greatest density of α2-3-sialic acid, which is the preferred ligand of CFH, did not colocalize with endogenous CFH. The level of sialic acids at the BrM/choroid interface of macula and peripheral retina of individuals with AMD were significantly reduced. Conclusions: The sialome of the human retina is altered in AMD. This can affect CFH binding and consequently, alternative complement pathway regulation.
Open AccessThe sialome of the retina, alteration in age-related macular degeneration (AMD) pathology and potential impacts on Complement Factor H
Purpose: Little is known about sialic acids of the human retina, despite their integral role in self/non-self-discrimination by complement factor H (CFH), the alternative complement pathway inhibitor. Methods: A custom sialoglycan microarray was used to characterize the sialic acid-binding specificity of native CFH or recombinant molecules where IgG Fc was fused to CFH domains 16-20 (contains a sialic acid-binding site), domains 6-7 (contains a glycosaminoglycan-binding site) or the CFH-related proteins (CFHRs) 1 and 3. We analyzed macular and peripheral retinal tissue from post-mortem ocular globes for amount, type, and presentation (glycosidic linkage type) of sialic acid in individuals with age-related macular degeneration (AMD) and age-matched controls using fluorescent lectins and antibodies to detect sialic acid and endogenous CFH. Released sialic acids from neural retina, retinal pigmented epithelium (RPE) cells and the Bruch’s membrane (BrM) were labelled with 1,2-diamino-4,5-methylenedioxybenzene-2HCl (DMB), separated and quantified by high-performance liquid chromatography (DMB-HPLC). Results: Both native CFH and the recombinant CFH domains 16-20 recognized Neu5Ac and Neu5Gc that is α2-3-linked to the underlying galactose. 4- O -Actylation of sialic acid and sulfation of GlcNAc did not inhibit binding. Different linkage types of sialic acid were localized at different layers of the retina. The greatest density of α2-3-sialic acid, which is the preferred ligand of CFH, did not colocalize with endogenous CFH. The level of sialic acids at the BrM/choroid interface of macula and peripheral retina of individuals with AMD were significantly reduced. Conclusions: The sialome of the human retina is altered in AMD. This can affect CFH binding and consequently, alternative complement pathway regulation.
- Open Access
Broad-Spectrum Legionaminic Acid-Specific Antibodies in Pooled Human IgGs Revealed by Glycan Microarrays with Chemoenzymatically Synthesized Nonulosonosides
The presence and the level of antibodies in human sera against bacterial glycans are indications of prior encounters with similar antigens and/or the bacteria that express them by the immune system. An increasing number of pathogenic bacteria that cause human diseases have been shown to express polysaccharides containing a bacterial nonulosonic acid called 5,7-di-N-acetyllegionaminic acid (Leg5,7Ac2). To investigate the immune recognition of Leg5,7Ac2, which is critical for the fight against bacterial infections, a highly effective chemoenzymatic synthon strategy was applied to construct a library of α2–3/6-linked Leg5,7Ac2-glycans via their diazido-derivatives (Leg5,7diN3-glycans) formed by efficient one-pot three-enzyme (OP3E) synthetic systems from a diazido-derivative of a six-carbon monosaccharide precursor. Glycan microarray studies using this synthetic library of a Leg5,7Ac2-capped collection of diverse underlying glycan carriers and their matched sialoside counterparts revealed specific recognition of Leg5,7Ac2 by human IgG antibodies pooled from thousands of healthy donors (IVIG), suggesting prior human encounters with Leg5,7Ac2-expressing pathogenic bacteria at the population level. These biologically relevant Leg5,7Ac2-glycans and their immune recognition assays are important tools to begin elucidating their biological roles, particularly in the context of infection and host–pathogen interactions.
Open AccessBroad-Spectrum Legionaminic Acid-Specific Antibodies in Pooled Human IgGs Revealed by Glycan Microarrays with Chemoenzymatically Synthesized Nonulosonosides
The presence and the level of antibodies in human sera against bacterial glycans are indications of prior encounters with similar antigens and/or the bacteria that express them by the immune system. An increasing number of pathogenic bacteria that cause human diseases have been shown to express polysaccharides containing a bacterial nonulosonic acid called 5,7-di-N-acetyllegionaminic acid (Leg5,7Ac2). To investigate the immune recognition of Leg5,7Ac2, which is critical for the fight against bacterial infections, a highly effective chemoenzymatic synthon strategy was applied to construct a library of α2–3/6-linked Leg5,7Ac2-glycans via their diazido-derivatives (Leg5,7diN3-glycans) formed by efficient one-pot three-enzyme (OP3E) synthetic systems from a diazido-derivative of a six-carbon monosaccharide precursor. Glycan microarray studies using this synthetic library of a Leg5,7Ac2-capped collection of diverse underlying glycan carriers and their matched sialoside counterparts revealed specific recognition of Leg5,7Ac2 by human IgG antibodies pooled from thousands of healthy donors (IVIG), suggesting prior human encounters with Leg5,7Ac2-expressing pathogenic bacteria at the population level. These biologically relevant Leg5,7Ac2-glycans and their immune recognition assays are important tools to begin elucidating their biological roles, particularly in the context of infection and host–pathogen interactions.
- 29 November 2021
- Published by Wiley in ChemCatChem
- Vol. 14 (2)
One‐pot Multienzyme (OPME) Chemoenzymatic Synthesis of Brain Ganglioside Glycans with Human ST3GAL II Expressed in E. coli
A human sialyltransferase ST3GAL II (hST3GAL II) was successfully expressed in Escherichia coli as an active soluble fusion protein with an N‐terminal maltose‐binding protein (MBP) and a C‐terminal hexa‐histidine tag. It was used as an efficient catalyst in a one‐pot multienzyme (OPME) sialylation system for high‐yield production of the glycans of ganglioside GM1b and highly sialylated brain gangliosides GD1a and GT1b. Further sialylation of GM1b and GD1a glycans using a bacterial α2–8‐sialyltransferase in another OPME sialylation reaction led to the formation of the glycans of GD1c and brain ganglioside GT1a, respectively. The lower reverse glycosylation activity of the recombinant hST3GAL II compared to its bacterial sialyltransferase counterpart simplifies the handling of enzymatic synthetic reactions and has an advantage for future use in automated chemoenzymatic synthetic processes.
- 29 November 2021
- Published by Wiley in ChemCatChem
- Vol. 14 (2)
One‐pot Multienzyme (OPME) Chemoenzymatic Synthesis of Brain Ganglioside Glycans with Human ST3GAL II Expressed in E. coli
A human sialyltransferase ST3GAL II (hST3GAL II) was successfully expressed in Escherichia coli as an active soluble fusion protein with an N‐terminal maltose‐binding protein (MBP) and a C‐terminal hexa‐histidine tag. It was used as an efficient catalyst in a one‐pot multienzyme (OPME) sialylation system for high‐yield production of the glycans of ganglioside GM1b and highly sialylated brain gangliosides GD1a and GT1b. Further sialylation of GM1b and GD1a glycans using a bacterial α2–8‐sialyltransferase in another OPME sialylation reaction led to the formation of the glycans of GD1c and brain ganglioside GT1a, respectively. The lower reverse glycosylation activity of the recombinant hST3GAL II compared to its bacterial sialyltransferase counterpart simplifies the handling of enzymatic synthetic reactions and has an advantage for future use in automated chemoenzymatic synthetic processes.
- 12 October 2021
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 86 (21) , 14381-14397
Chemoenzymatic Synthesis of Sialosides Containing 7-N- or 7,9-Di-N-acetyl Sialic Acid as Stable O-Acetyl Analogues for Probing Sialic Acid-Binding Proteins
A novel chemoenzymatic synthon strategy has been developed to construct a comprehensive library of α2–3- and α2–6-linked sialosides containing 7-N- or 7,9-di-N-acetyl sialic acid, the stable analogue of naturally occurring 7-O-acetyl- or 7,9-di-O-acetyl-sialic acid. Diazido and triazido-mannose derivatives that were readily synthesized chemically from inexpensive galactose were shown to be effective chemoenzymatic synthons. Together with bacterial sialoside biosynthetic enzymes with remarkable substrate promiscuity, they were successfully used in one-pot multienzyme (OPME) sialylation systems for highly efficient synthesis of sialosides containing multiple azido groups. Conversion of the azido groups to N-acetyl groups generated the desired sialosides. The hydrophobic and UV-detectable benzyloxycarbonyl (Cbz) group introduced in the synthetic acceptors of sialyltransferases was used as a removable protecting group for the propylamine aglycon of the target sialosides. The resulting N-acetyl sialosides were novel stable probes for sialic acid-binding proteins such as plant lectin MAL II, which bond strongly to sialyl T antigens with or without an N-acetyl at C7 or at both C7 and C9 in the sialic acid.
- 12 October 2021
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 86 (21) , 14381-14397
Chemoenzymatic Synthesis of Sialosides Containing 7-N- or 7,9-Di-N-acetyl Sialic Acid as Stable O-Acetyl Analogues for Probing Sialic Acid-Binding Proteins
A novel chemoenzymatic synthon strategy has been developed to construct a comprehensive library of α2–3- and α2–6-linked sialosides containing 7-N- or 7,9-di-N-acetyl sialic acid, the stable analogue of naturally occurring 7-O-acetyl- or 7,9-di-O-acetyl-sialic acid. Diazido and triazido-mannose derivatives that were readily synthesized chemically from inexpensive galactose were shown to be effective chemoenzymatic synthons. Together with bacterial sialoside biosynthetic enzymes with remarkable substrate promiscuity, they were successfully used in one-pot multienzyme (OPME) sialylation systems for highly efficient synthesis of sialosides containing multiple azido groups. Conversion of the azido groups to N-acetyl groups generated the desired sialosides. The hydrophobic and UV-detectable benzyloxycarbonyl (Cbz) group introduced in the synthetic acceptors of sialyltransferases was used as a removable protecting group for the propylamine aglycon of the target sialosides. The resulting N-acetyl sialosides were novel stable probes for sialic acid-binding proteins such as plant lectin MAL II, which bond strongly to sialyl T antigens with or without an N-acetyl at C7 or at both C7 and C9 in the sialic acid.
- 9 November 2020
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 85 (24) , 16157-16165
A Chemoenzymatic Synthon Strategy for Synthesizing N-Acetyl Analogues of O-Acetylated N. meningitidis W Capsular Polysaccharide Oligosaccharides
O-Acetylated sialic acid has been found in the Neisseria meningitidis serogroup W (NmW) capsular polysaccharide (CPS) and is a required structural component of clinically used NmW CPS-based polysaccharide and polysaccharide–conjugate vaccines. The role of sialic acid O-acetylation in NmW CPS, however, is not clearly understood. This is partially due to the lack of a precise control of the percentage and the location of O-acetylation which is labile and susceptible to migration. We explore chemoenzymatic synthetic strategies for preparing N-acetylated analogues of O-acetylated NmW CPS oligosaccharides which can serve as structurally stable probe mimics. Substrate specificity studies of NmW CPS polymerase (NmSiaDW) identified 4-azido-4-deoxy-N-acetylmannosamine (ManNAc4N3) and 6-azido-6-deoxy-N-acetylmannosamine (ManNAc6N3) as suitable chemoenzymatic synthons for synthesizing N-acetyl analogues of NmW CPS oligosaccharides containing 7-O-acetyl-N-acetylneuraminic acid (Neu5,7Ac2) and/or 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac2). The synthesis was achieved by NmSiaDW-dependent sequential one-pot multienzyme (OPME) strategy with in situ generation of the corresponding sugar nucleotides from simple monosaccharides or derivatives to form N3-oligosaccharides which were converted to the desired NAc-oligosaccharides by an efficient one-step chemical transformation.
- 9 November 2020
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 85 (24) , 16157-16165
A Chemoenzymatic Synthon Strategy for Synthesizing N-Acetyl Analogues of O-Acetylated N. meningitidis W Capsular Polysaccharide Oligosaccharides
O-Acetylated sialic acid has been found in the Neisseria meningitidis serogroup W (NmW) capsular polysaccharide (CPS) and is a required structural component of clinically used NmW CPS-based polysaccharide and polysaccharide–conjugate vaccines. The role of sialic acid O-acetylation in NmW CPS, however, is not clearly understood. This is partially due to the lack of a precise control of the percentage and the location of O-acetylation which is labile and susceptible to migration. We explore chemoenzymatic synthetic strategies for preparing N-acetylated analogues of O-acetylated NmW CPS oligosaccharides which can serve as structurally stable probe mimics. Substrate specificity studies of NmW CPS polymerase (NmSiaDW) identified 4-azido-4-deoxy-N-acetylmannosamine (ManNAc4N3) and 6-azido-6-deoxy-N-acetylmannosamine (ManNAc6N3) as suitable chemoenzymatic synthons for synthesizing N-acetyl analogues of NmW CPS oligosaccharides containing 7-O-acetyl-N-acetylneuraminic acid (Neu5,7Ac2) and/or 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac2). The synthesis was achieved by NmSiaDW-dependent sequential one-pot multienzyme (OPME) strategy with in situ generation of the corresponding sugar nucleotides from simple monosaccharides or derivatives to form N3-oligosaccharides which were converted to the desired NAc-oligosaccharides by an efficient one-step chemical transformation.